Global Xeloda
Global Xeloda

Xeloda Comprehensive Study by Application (Colon Cancer, Rectal Cancer, Breast Cancer, Gastric Cancer, Others), Strength (500mg, 100mg) Players and Region - Global Market Outlook to 2026

Xeloda Market Segmented into XX Submarkets. | Forecast Years: 2021- 2026  

May 2021 Edition 215 Pages 200 Tables & Figures
  • Summary
  • Market Segments
  • Table of Content
  • List of Tables & Figures
  • Companies Mentioned
Industry Background:
Xeloda is the trade name for Capecitabine. It is a chemotherapy drug that is used to treat breast cancer, gastric cancer, and colorectal cancer. It's often combined with docetaxel in the treatment of breast cancer. It is taken orally. Market growth is aided by factors such as rising cancer incidence and increased demand for target drug therapy. Furthermore, rising healthcare expenditures and increased government and private-sector investment in cancer treatment or assistance programs are expected to drive market growth. Patients have benefited from benefits such as improved access and availability in the form of the oral dose. Increased prescriptions of capecitabine in conjunction with docetaxel, pertuzumab, and trastuzumab to extend overall survival in metastatic breast cancer are also expected to fuel the segment's growth.This growth is primarily driven by Rising Prevalence of Cancer and Increasing Awareness and Spending on Healthcare.

Globally, a noticeable market trend is evident Development in Oncology Treatment Drugs. Major Players, such as Teva Pharmaceuticals, Inc. (Israel), Hoffmann-La Roche AG (Switzerland), Mylan N.V. (United States), Hikma Pharmaceuticals PLC (United Kingdom), Cipla Inc. (India), Dr. Reddy's Laboratories Ltd. (India), Fresenius SE & Co. KGaA (Germany), Intas Pharmaceuticals Limited (India), Sun Pharmaceutical Industries Limited and Torrent Pharmaceuticals (India) etc have either set up their manufacturing facilities or are planning to start new provision in the dominated region in the upcoming years.

February 2021 Dr Reddy's Labs announced the launch of Capecitabine Tablets, USP a therapeutic equivalent generic version of Xeloda (capecitabine) Tablets approved by the US Food and Drug Administration (USFDA).

Market Drivers
  • Rising Prevalence of Cancer
  • Increasing Awareness and Spending on Healthcare

Market Trend
  • Development in Oncology Treatment Drugs

Restraints
  • Adverse Side Effects of Drugs

Opportunities
Increase Investment in R&D in Cancer Treatment and Various Governments Initiatives to Increase Awareness and Investment
Challenges
Stringent Regulatory Factors

AdvanceMarketAnalytics follow a focused and realistic research framework that provides the ability to study the crucial market dynamics in several regions across the world. Moreover, an in-depth assessment is mostly conducted by our analysts on geographical regions to provide clients and businesses the opportunity to dominate in niche markets and expand in emerging markets across the globe. This market research study also showcase the spontaneously changing Players landscape impacting the growth of the market. Furthermore, our market researchers extensively analyse the products and services offered by multiple players competing to increase their market share and presence.

Customization of the Report:
AMA Research & Media features not only specific market forecasts, but also include significant value-added commentary on:
Market Trends
Technological Trends and Innovations
Regulatory Trends & Policies
Market Maturity Indicators
Market Share Movements
Growth Drivers and Constraints
New Entrants into the Market & Entry/Exit Barriers
Consumer Demographics
Supporting Company Financial and Cash Flow Planning
Open Up New Markets
To Seize Powerful Market Opportunities
Key Decision in Planning and to Further Expand Market Share
Identify Key Business Segments, Market Proposition & Gap Analysis
Report Objectives / Segmentation Covered
By Application
  • Colon Cancer
  • Rectal Cancer
  • Breast Cancer
  • Gastric Cancer
  • Others
By Strength
  • 500mg
  • 100mg

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Rising Prevalence of Cancer
      • 3.2.2. Increasing Awareness and Spending on Healthcare
    • 3.3. Market Challenges
      • 3.3.1. Stringent Regulatory Factors
    • 3.4. Market Trends
      • 3.4.1. Development in Oncology Treatment Drugs
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Xeloda, by Application, Strength and Region (value) (2015-2020)
    • 5.1. Introduction
    • 5.2. Global Xeloda (Value)
      • 5.2.1. Global Xeloda by: Application (Value)
        • 5.2.1.1. Colon Cancer
        • 5.2.1.2. Rectal Cancer
        • 5.2.1.3. Breast Cancer
        • 5.2.1.4. Gastric Cancer
        • 5.2.1.5. Others
      • 5.2.2. Global Xeloda by: Strength (Value)
        • 5.2.2.1. 500mg
        • 5.2.2.2. 100mg
      • 5.2.3. Global Xeloda Region
        • 5.2.3.1. South America
          • 5.2.3.1.1. Brazil
          • 5.2.3.1.2. Argentina
          • 5.2.3.1.3. Rest of South America
        • 5.2.3.2. Asia Pacific
          • 5.2.3.2.1. China
          • 5.2.3.2.2. Japan
          • 5.2.3.2.3. India
          • 5.2.3.2.4. South Korea
          • 5.2.3.2.5. Taiwan
          • 5.2.3.2.6. Australia
          • 5.2.3.2.7. Rest of Asia-Pacific
        • 5.2.3.3. Europe
          • 5.2.3.3.1. Germany
          • 5.2.3.3.2. France
          • 5.2.3.3.3. Italy
          • 5.2.3.3.4. United Kingdom
          • 5.2.3.3.5. Netherlands
          • 5.2.3.3.6. Rest of Europe
        • 5.2.3.4. MEA
          • 5.2.3.4.1. Middle East
          • 5.2.3.4.2. Africa
        • 5.2.3.5. North America
          • 5.2.3.5.1. United States
          • 5.2.3.5.2. Canada
          • 5.2.3.5.3. Mexico
  • 6. Xeloda: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2020)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Teva Pharmaceuticals, Inc. (Israel)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Hoffmann-La Roche AG (Switzerland)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Mylan N.V. (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Hikma Pharmaceuticals PLC (United Kingdom)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Cipla Inc. (India)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Dr. Reddy's Laboratories Ltd. (India)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Fresenius SE & Co. KGaA (Germany)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Intas Pharmaceuticals Limited (India)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Sun Pharmaceutical Industries Limited
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Torrent Pharmaceuticals (India)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Xeloda Sale, by Application, Strength and Region (value) (2021-2026)
    • 7.1. Introduction
    • 7.2. Global Xeloda (Value)
      • 7.2.1. Global Xeloda by: Application (Value)
        • 7.2.1.1. Colon Cancer
        • 7.2.1.2. Rectal Cancer
        • 7.2.1.3. Breast Cancer
        • 7.2.1.4. Gastric Cancer
        • 7.2.1.5. Others
      • 7.2.2. Global Xeloda by: Strength (Value)
        • 7.2.2.1. 500mg
        • 7.2.2.2. 100mg
      • 7.2.3. Global Xeloda Region
        • 7.2.3.1. South America
          • 7.2.3.1.1. Brazil
          • 7.2.3.1.2. Argentina
          • 7.2.3.1.3. Rest of South America
        • 7.2.3.2. Asia Pacific
          • 7.2.3.2.1. China
          • 7.2.3.2.2. Japan
          • 7.2.3.2.3. India
          • 7.2.3.2.4. South Korea
          • 7.2.3.2.5. Taiwan
          • 7.2.3.2.6. Australia
          • 7.2.3.2.7. Rest of Asia-Pacific
        • 7.2.3.3. Europe
          • 7.2.3.3.1. Germany
          • 7.2.3.3.2. France
          • 7.2.3.3.3. Italy
          • 7.2.3.3.4. United Kingdom
          • 7.2.3.3.5. Netherlands
          • 7.2.3.3.6. Rest of Europe
        • 7.2.3.4. MEA
          • 7.2.3.4.1. Middle East
          • 7.2.3.4.2. Africa
        • 7.2.3.5. North America
          • 7.2.3.5.1. United States
          • 7.2.3.5.2. Canada
          • 7.2.3.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Xeloda: by Application(USD Million)
  • Table 2. Xeloda Colon Cancer , by Region USD Million (2015-2020)
  • Table 3. Xeloda Rectal Cancer , by Region USD Million (2015-2020)
  • Table 4. Xeloda Breast Cancer , by Region USD Million (2015-2020)
  • Table 5. Xeloda Gastric Cancer , by Region USD Million (2015-2020)
  • Table 6. Xeloda Others , by Region USD Million (2015-2020)
  • Table 7. Xeloda: by Strength(USD Million)
  • Table 8. Xeloda 500mg , by Region USD Million (2015-2020)
  • Table 9. Xeloda 100mg , by Region USD Million (2015-2020)
  • Table 10. South America Xeloda, by Country USD Million (2015-2020)
  • Table 11. South America Xeloda, by Application USD Million (2015-2020)
  • Table 12. South America Xeloda, by Strength USD Million (2015-2020)
  • Table 13. Brazil Xeloda, by Application USD Million (2015-2020)
  • Table 14. Brazil Xeloda, by Strength USD Million (2015-2020)
  • Table 15. Argentina Xeloda, by Application USD Million (2015-2020)
  • Table 16. Argentina Xeloda, by Strength USD Million (2015-2020)
  • Table 17. Rest of South America Xeloda, by Application USD Million (2015-2020)
  • Table 18. Rest of South America Xeloda, by Strength USD Million (2015-2020)
  • Table 19. Asia Pacific Xeloda, by Country USD Million (2015-2020)
  • Table 20. Asia Pacific Xeloda, by Application USD Million (2015-2020)
  • Table 21. Asia Pacific Xeloda, by Strength USD Million (2015-2020)
  • Table 22. China Xeloda, by Application USD Million (2015-2020)
  • Table 23. China Xeloda, by Strength USD Million (2015-2020)
  • Table 24. Japan Xeloda, by Application USD Million (2015-2020)
  • Table 25. Japan Xeloda, by Strength USD Million (2015-2020)
  • Table 26. India Xeloda, by Application USD Million (2015-2020)
  • Table 27. India Xeloda, by Strength USD Million (2015-2020)
  • Table 28. South Korea Xeloda, by Application USD Million (2015-2020)
  • Table 29. South Korea Xeloda, by Strength USD Million (2015-2020)
  • Table 30. Taiwan Xeloda, by Application USD Million (2015-2020)
  • Table 31. Taiwan Xeloda, by Strength USD Million (2015-2020)
  • Table 32. Australia Xeloda, by Application USD Million (2015-2020)
  • Table 33. Australia Xeloda, by Strength USD Million (2015-2020)
  • Table 34. Rest of Asia-Pacific Xeloda, by Application USD Million (2015-2020)
  • Table 35. Rest of Asia-Pacific Xeloda, by Strength USD Million (2015-2020)
  • Table 36. Europe Xeloda, by Country USD Million (2015-2020)
  • Table 37. Europe Xeloda, by Application USD Million (2015-2020)
  • Table 38. Europe Xeloda, by Strength USD Million (2015-2020)
  • Table 39. Germany Xeloda, by Application USD Million (2015-2020)
  • Table 40. Germany Xeloda, by Strength USD Million (2015-2020)
  • Table 41. France Xeloda, by Application USD Million (2015-2020)
  • Table 42. France Xeloda, by Strength USD Million (2015-2020)
  • Table 43. Italy Xeloda, by Application USD Million (2015-2020)
  • Table 44. Italy Xeloda, by Strength USD Million (2015-2020)
  • Table 45. United Kingdom Xeloda, by Application USD Million (2015-2020)
  • Table 46. United Kingdom Xeloda, by Strength USD Million (2015-2020)
  • Table 47. Netherlands Xeloda, by Application USD Million (2015-2020)
  • Table 48. Netherlands Xeloda, by Strength USD Million (2015-2020)
  • Table 49. Rest of Europe Xeloda, by Application USD Million (2015-2020)
  • Table 50. Rest of Europe Xeloda, by Strength USD Million (2015-2020)
  • Table 51. MEA Xeloda, by Country USD Million (2015-2020)
  • Table 52. MEA Xeloda, by Application USD Million (2015-2020)
  • Table 53. MEA Xeloda, by Strength USD Million (2015-2020)
  • Table 54. Middle East Xeloda, by Application USD Million (2015-2020)
  • Table 55. Middle East Xeloda, by Strength USD Million (2015-2020)
  • Table 56. Africa Xeloda, by Application USD Million (2015-2020)
  • Table 57. Africa Xeloda, by Strength USD Million (2015-2020)
  • Table 58. North America Xeloda, by Country USD Million (2015-2020)
  • Table 59. North America Xeloda, by Application USD Million (2015-2020)
  • Table 60. North America Xeloda, by Strength USD Million (2015-2020)
  • Table 61. United States Xeloda, by Application USD Million (2015-2020)
  • Table 62. United States Xeloda, by Strength USD Million (2015-2020)
  • Table 63. Canada Xeloda, by Application USD Million (2015-2020)
  • Table 64. Canada Xeloda, by Strength USD Million (2015-2020)
  • Table 65. Mexico Xeloda, by Application USD Million (2015-2020)
  • Table 66. Mexico Xeloda, by Strength USD Million (2015-2020)
  • Table 67. Company Basic Information, Sales Area and Its Competitors
  • Table 68. Company Basic Information, Sales Area and Its Competitors
  • Table 69. Company Basic Information, Sales Area and Its Competitors
  • Table 70. Company Basic Information, Sales Area and Its Competitors
  • Table 71. Company Basic Information, Sales Area and Its Competitors
  • Table 72. Company Basic Information, Sales Area and Its Competitors
  • Table 73. Company Basic Information, Sales Area and Its Competitors
  • Table 74. Company Basic Information, Sales Area and Its Competitors
  • Table 75. Company Basic Information, Sales Area and Its Competitors
  • Table 76. Company Basic Information, Sales Area and Its Competitors
  • Table 77. Xeloda: by Application(USD Million)
  • Table 78. Xeloda Colon Cancer , by Region USD Million (2021-2026)
  • Table 79. Xeloda Rectal Cancer , by Region USD Million (2021-2026)
  • Table 80. Xeloda Breast Cancer , by Region USD Million (2021-2026)
  • Table 81. Xeloda Gastric Cancer , by Region USD Million (2021-2026)
  • Table 82. Xeloda Others , by Region USD Million (2021-2026)
  • Table 83. Xeloda: by Strength(USD Million)
  • Table 84. Xeloda 500mg , by Region USD Million (2021-2026)
  • Table 85. Xeloda 100mg , by Region USD Million (2021-2026)
  • Table 86. South America Xeloda, by Country USD Million (2021-2026)
  • Table 87. South America Xeloda, by Application USD Million (2021-2026)
  • Table 88. South America Xeloda, by Strength USD Million (2021-2026)
  • Table 89. Brazil Xeloda, by Application USD Million (2021-2026)
  • Table 90. Brazil Xeloda, by Strength USD Million (2021-2026)
  • Table 91. Argentina Xeloda, by Application USD Million (2021-2026)
  • Table 92. Argentina Xeloda, by Strength USD Million (2021-2026)
  • Table 93. Rest of South America Xeloda, by Application USD Million (2021-2026)
  • Table 94. Rest of South America Xeloda, by Strength USD Million (2021-2026)
  • Table 95. Asia Pacific Xeloda, by Country USD Million (2021-2026)
  • Table 96. Asia Pacific Xeloda, by Application USD Million (2021-2026)
  • Table 97. Asia Pacific Xeloda, by Strength USD Million (2021-2026)
  • Table 98. China Xeloda, by Application USD Million (2021-2026)
  • Table 99. China Xeloda, by Strength USD Million (2021-2026)
  • Table 100. Japan Xeloda, by Application USD Million (2021-2026)
  • Table 101. Japan Xeloda, by Strength USD Million (2021-2026)
  • Table 102. India Xeloda, by Application USD Million (2021-2026)
  • Table 103. India Xeloda, by Strength USD Million (2021-2026)
  • Table 104. South Korea Xeloda, by Application USD Million (2021-2026)
  • Table 105. South Korea Xeloda, by Strength USD Million (2021-2026)
  • Table 106. Taiwan Xeloda, by Application USD Million (2021-2026)
  • Table 107. Taiwan Xeloda, by Strength USD Million (2021-2026)
  • Table 108. Australia Xeloda, by Application USD Million (2021-2026)
  • Table 109. Australia Xeloda, by Strength USD Million (2021-2026)
  • Table 110. Rest of Asia-Pacific Xeloda, by Application USD Million (2021-2026)
  • Table 111. Rest of Asia-Pacific Xeloda, by Strength USD Million (2021-2026)
  • Table 112. Europe Xeloda, by Country USD Million (2021-2026)
  • Table 113. Europe Xeloda, by Application USD Million (2021-2026)
  • Table 114. Europe Xeloda, by Strength USD Million (2021-2026)
  • Table 115. Germany Xeloda, by Application USD Million (2021-2026)
  • Table 116. Germany Xeloda, by Strength USD Million (2021-2026)
  • Table 117. France Xeloda, by Application USD Million (2021-2026)
  • Table 118. France Xeloda, by Strength USD Million (2021-2026)
  • Table 119. Italy Xeloda, by Application USD Million (2021-2026)
  • Table 120. Italy Xeloda, by Strength USD Million (2021-2026)
  • Table 121. United Kingdom Xeloda, by Application USD Million (2021-2026)
  • Table 122. United Kingdom Xeloda, by Strength USD Million (2021-2026)
  • Table 123. Netherlands Xeloda, by Application USD Million (2021-2026)
  • Table 124. Netherlands Xeloda, by Strength USD Million (2021-2026)
  • Table 125. Rest of Europe Xeloda, by Application USD Million (2021-2026)
  • Table 126. Rest of Europe Xeloda, by Strength USD Million (2021-2026)
  • Table 127. MEA Xeloda, by Country USD Million (2021-2026)
  • Table 128. MEA Xeloda, by Application USD Million (2021-2026)
  • Table 129. MEA Xeloda, by Strength USD Million (2021-2026)
  • Table 130. Middle East Xeloda, by Application USD Million (2021-2026)
  • Table 131. Middle East Xeloda, by Strength USD Million (2021-2026)
  • Table 132. Africa Xeloda, by Application USD Million (2021-2026)
  • Table 133. Africa Xeloda, by Strength USD Million (2021-2026)
  • Table 134. North America Xeloda, by Country USD Million (2021-2026)
  • Table 135. North America Xeloda, by Application USD Million (2021-2026)
  • Table 136. North America Xeloda, by Strength USD Million (2021-2026)
  • Table 137. United States Xeloda, by Application USD Million (2021-2026)
  • Table 138. United States Xeloda, by Strength USD Million (2021-2026)
  • Table 139. Canada Xeloda, by Application USD Million (2021-2026)
  • Table 140. Canada Xeloda, by Strength USD Million (2021-2026)
  • Table 141. Mexico Xeloda, by Application USD Million (2021-2026)
  • Table 142. Mexico Xeloda, by Strength USD Million (2021-2026)
  • Table 143. Research Programs/Design for This Report
  • Table 144. Key Data Information from Secondary Sources
  • Table 145. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Xeloda: by Application USD Million (2015-2020)
  • Figure 5. Global Xeloda: by Strength USD Million (2015-2020)
  • Figure 6. South America Xeloda Share (%), by Country
  • Figure 7. Asia Pacific Xeloda Share (%), by Country
  • Figure 8. Europe Xeloda Share (%), by Country
  • Figure 9. MEA Xeloda Share (%), by Country
  • Figure 10. North America Xeloda Share (%), by Country
  • Figure 11. Global Xeloda share by Players 2020 (%)
  • Figure 12. Global Xeloda share by Players (Top 3) 2020(%)
  • Figure 13. Global Xeloda share by Players (Top 5) 2020(%)
  • Figure 14. BCG Matrix for key Companies
  • Figure 15. Teva Pharmaceuticals, Inc. (Israel) Revenue, Net Income and Gross profit
  • Figure 16. Teva Pharmaceuticals, Inc. (Israel) Revenue: by Geography 2020
  • Figure 17. Hoffmann-La Roche AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 18. Hoffmann-La Roche AG (Switzerland) Revenue: by Geography 2020
  • Figure 19. Mylan N.V. (United States) Revenue, Net Income and Gross profit
  • Figure 20. Mylan N.V. (United States) Revenue: by Geography 2020
  • Figure 21. Hikma Pharmaceuticals PLC (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 22. Hikma Pharmaceuticals PLC (United Kingdom) Revenue: by Geography 2020
  • Figure 23. Cipla Inc. (India) Revenue, Net Income and Gross profit
  • Figure 24. Cipla Inc. (India) Revenue: by Geography 2020
  • Figure 25. Dr. Reddy's Laboratories Ltd. (India) Revenue, Net Income and Gross profit
  • Figure 26. Dr. Reddy's Laboratories Ltd. (India) Revenue: by Geography 2020
  • Figure 27. Fresenius SE & Co. KGaA (Germany) Revenue, Net Income and Gross profit
  • Figure 28. Fresenius SE & Co. KGaA (Germany) Revenue: by Geography 2020
  • Figure 29. Intas Pharmaceuticals Limited (India) Revenue, Net Income and Gross profit
  • Figure 30. Intas Pharmaceuticals Limited (India) Revenue: by Geography 2020
  • Figure 31. Sun Pharmaceutical Industries Limited Revenue, Net Income and Gross profit
  • Figure 32. Sun Pharmaceutical Industries Limited Revenue: by Geography 2020
  • Figure 33. Torrent Pharmaceuticals (India) Revenue, Net Income and Gross profit
  • Figure 34. Torrent Pharmaceuticals (India) Revenue: by Geography 2020
  • Figure 35. Global Xeloda: by Application USD Million (2021-2026)
  • Figure 36. Global Xeloda: by Strength USD Million (2021-2026)
  • Figure 37. South America Xeloda Share (%), by Country
  • Figure 38. Asia Pacific Xeloda Share (%), by Country
  • Figure 39. Europe Xeloda Share (%), by Country
  • Figure 40. MEA Xeloda Share (%), by Country
  • Figure 41. North America Xeloda Share (%), by Country
Some of the key companies/manufacturers profiled in the report
  • Teva Pharmaceuticals, Inc. (Israel)
  • Hoffmann-La Roche AG (Switzerland)
  • Mylan N.V. (United States)
  • Hikma Pharmaceuticals PLC (United Kingdom)
  • Cipla Inc. (India)
  • Dr. Reddy's Laboratories Ltd. (India)
  • Fresenius SE & Co. KGaA (Germany)
  • Intas Pharmaceuticals Limited (India)
  • Sun Pharmaceutical Industries Limited
  • Torrent Pharmaceuticals (India)
Select License Type
Sample Report Enquiry Before Buy Request Discount

Speak with Analyst

Want to find out more about this report?

Get Free Consultation